The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.

Détails

Ressource 1Télécharger: BIB_0FE586F092BC.P001.pdf (1607.65 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_0FE586F092BC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.
Périodique
Journal of Immunology
Auteur(s)
Trabanelli S., Očadlíková D., Ciciarello M., Salvestrini V., Lecciso M., Jandus C., Metz R., Evangelisti C., Laury-Kleintop L., Romero P., Prendergast G.C., Curti A., Lemoli R.M.
ISSN
1550-6606 (Electronic)
ISSN-L
0022-1767
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
192
Numéro
3
Pages
1231-1240
Langue
anglais
Résumé
Dendritic cells (DCs) are professional APCs that have a role in the initiation of adaptive immune responses and tolerance. Among the tolerogenic mechanisms, the expression of the enzyme IDO1 represents an effective tool to generate T regulatory cells. In humans, different DC subsets express IDO1, but less is known about the IDO1-related enzyme IDO2. In this study, we found a different pattern of expression and regulation between IDO1 and IDO2 in human circulating DCs. At the protein level, IDO1 is expressed only in circulating myeloid DCs (mDCs) and is modulated by PGE2, whereas IDO2 is expressed in both mDCs and plasmacytoid DCs and is not modulated by PGE2. In healthy subjects, IDO1 expression requires the presence of PGE2 and needs continuous transcription and translation, whereas IDO2 expression is constitutive, independent from suppressor of cytokine signaling 3 activity. Conversely, in patients suffering from inflammatory arthritis, circulating DCs express both IDO1 and IDO2. At the functional level, both mDCs and plasmacytoid DCs generate T regulatory cells through an IDO1/IDO2-dependent mechanism. We conclude that, in humans, whereas IDO1 provides an additional mechanism of tolerance induced by proinflammatory mediators, IDO2 is stably expressed in steady-state conditions and may contribute to the homeostatic tolerogenic capacity of DCs.
Mots-clé
Arthritis, Psoriatic/immunology, Arthritis, Psoriatic/pathology, Arthritis, Rheumatoid/immunology, Arthritis, Rheumatoid/pathology, Cells, Cultured, Dendritic Cells/classification, Dendritic Cells/enzymology, Dinoprostone/pharmacology, Dinoprostone/physiology, Enzyme Induction/drug effects, Homeostasis, Humans, Immune Tolerance, Indoleamine-Pyrrole 2,3,-Dioxygenase/biosynthesis, Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics, Monocytes/cytology, Monocytes/drug effects, Organ Specificity, Protein Biosynthesis/drug effects, RNA Interference, RNA, Small Interfering/pharmacology, Spondylitis, Ankylosing/immunology, Spondylitis, Ankylosing/pathology, Suppressor of Cytokine Signaling Proteins/antagonists & inhibitors, T-Lymphocytes, Regulatory/immunology, Transcription, Genetic/drug effects, Tryptophan/metabolism, Up-Regulation/drug effects
Pubmed
Création de la notice
27/10/2014 16:09
Dernière modification de la notice
20/08/2019 13:36
Données d'usage